Guangdong Marubi Biotechnology Co Ltd
SSE:603983
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Guangdong Marubi Biotechnology Co Ltd
Net Income (Common)
Guangdong Marubi Biotechnology Co Ltd
Net Income (Common) Peer Comparison
1044
603605
300957
300146
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
G
|
Guangdong Marubi Biotechnology Co Ltd
SSE:603983
|
Net Income (Common)
¥291.4m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Hengan International Group Company Ltd
HKEX:1044
|
Net Income (Common)
¥2.8B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-1%
|
|
|
Proya Cosmetics Co Ltd
SSE:603605
|
Net Income (Common)
¥1.3B
|
CAGR 3-Years
36%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Yunnan Botanee Bio-Technology Group Co Ltd
SZSE:300957
|
Net Income (Common)
¥756.8m
|
CAGR 3-Years
12%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
By-health Co Ltd
SZSE:300146
|
Net Income (Common)
¥1.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
G
|
Giant Biogene Holding Co Ltd
HKEX:2367
|
Net Income (Common)
¥1.5B
|
CAGR 3-Years
21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Guangdong Marubi Biotechnology Co Ltd's Net Income (Common)?
Net Income (Common)
291.4m
CNY
Based on the financial report for Mar 31, 2024, Guangdong Marubi Biotechnology Co Ltd's Net Income (Common) amounts to 291.4m CNY.
What is Guangdong Marubi Biotechnology Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-8%
Over the last year, the Net Income (Common) growth was 56%. The average annual Net Income (Common) growth rates for Guangdong Marubi Biotechnology Co Ltd have been -13% over the past three years , -8% over the past five years .
You don't have any saved screeners yet
